Across TCGA pan-cancer cohorts, PLEKHN1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PLEKHN1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PLEKHN1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PLEKHN1 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where PLEKHN1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLEKHN1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−0.850	<.001	8	view →
LUAD	All	II,III,IV	−0.597	<.001	7	view →
LSCC	All	All	−1.030	<.001	6	view →
PDAC	Female	All	+0.499	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PLEKHN1 RNA expression & survival · all PLEKHN1 data types